Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.

Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB.

Cancer Res. 2005 Jun 1;65(11):4789-98.

2.

Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.

Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, Baumgartner KJ, Roebuck BD, Liby KT, Yore MM, Honda T, Gribble GW, Sporn MB, Kensler TW.

Cancer Res. 2006 Feb 15;66(4):2488-94.

3.

Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.

Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW.

Mol Cancer Ther. 2007 Jan;6(1):154-62.

4.

Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention.

Cao M, Onyango EO, Williams CR, Royce DB, Gribble GW, Sporn MB, Liby KT.

Pharmacol Res. 2015 Oct;100:135-47. doi: 10.1016/j.phrs.2015.07.024. Epub 2015 Jul 31.

PMID:
26238177
5.

CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes.

Reisman SA, Buckley DB, Tanaka Y, Klaassen CD.

Toxicol Appl Pharmacol. 2009 Apr 1;236(1):109-14. doi: 10.1016/j.taap.2008.12.024. Epub 2009 Jan 20.

6.

Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.

Thimmulappa RK, Fuchs RJ, Malhotra D, Scollick C, Traore K, Bream JH, Trush MA, Liby KT, Sporn MB, Kensler TW, Biswal S.

Antioxid Redox Signal. 2007 Nov;9(11):1963-70.

7.

Cytoprotection of human endothelial cells against oxidative stress by 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im): application of systems biology to understand the mechanism of action.

Wang X, Bynum JA, Stavchansky S, Bowman PD.

Eur J Pharmacol. 2014 Jul 5;734:122-31. doi: 10.1016/j.ejphar.2014.03.033. Epub 2014 Apr 3.

PMID:
24703885
8.

The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice.

Reddy NM, Suryanaraya V, Yates MS, Kleeberger SR, Hassoun PM, Yamamoto M, Liby KT, Sporn MB, Kensler TW, Reddy SP.

Am J Respir Crit Care Med. 2009 Nov 1;180(9):867-74. doi: 10.1164/rccm.200905-0670OC. Epub 2009 Aug 13.

9.

Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN.

Pitha-Rowe I, Liby K, Royce D, Sporn M.

Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5339-47. doi: 10.1167/iovs.09-3648. Epub 2009 Jun 3.

PMID:
19494206
10.

Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.

Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB.

Cancer Res. 2003 Mar 15;63(6):1371-6.

11.

Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.

To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT.

Carcinogenesis. 2015 Jul;36(7):769-81. doi: 10.1093/carcin/bgv061. Epub 2015 May 4.

12.

Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide.

Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, Liby KT, Sporn MB, Yamamoto M, Kensler TW.

Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44. doi: 10.1016/j.ejphar.2009.08.022. Epub 2009 Aug 19.

13.

Pharmacological induction of heme oxygenase-1 by a triterpenoid protects neurons against ischemic injury.

Zhang F, Wang S, Zhang M, Weng Z, Li P, Gan Y, Zhang L, Cao G, Gao Y, Leak RK, Sporn MB, Chen J.

Stroke. 2012 May;43(5):1390-7. doi: 10.1161/STROKEAHA.111.647420. Epub 2012 Mar 29.

14.
15.

The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.

Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E, Sporn MB.

Clin Cancer Res. 2003 Jul;9(7):2798-806.

16.
17.

CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells.

Kim EH, Deng CX, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2011 Mar;4(3):425-34. doi: 10.1158/1940-6207.CAPR-10-0153.

18.

Neuroprotective role of Nrf2 for retinal ganglion cells in ischemia-reperfusion.

Xu Z, Cho H, Hartsock MJ, Mitchell KL, Gong J, Wu L, Wei Y, Wang S, Thimmulappa RK, Sporn MB, Biswal S, Welsbie DS, Duh EJ.

J Neurochem. 2015 Apr;133(2):233-41. doi: 10.1111/jnc.13064. Epub 2015 Mar 4.

19.

Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.

Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.

Cancer Res. 2005 Jun 1;65(11):4799-808.

20.

Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice.

Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, Kensler TW.

Carcinogenesis. 2009 Jun;30(6):1024-31. doi: 10.1093/carcin/bgp100. Epub 2009 Apr 21.

Supplemental Content

Support Center